Topsy turvy times for industry’s mid and small cap stocks in the first quarter
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
AACR 2019 – Xospata meets the conditions of its US approval
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
Astra shakes hands with Daiichi to take on Roche
UK group bets billions on an Her2 project slated for late-line patients and those with lower expression of the target protein.
US regulator wipes the smile off Immunomedics’ face
Issues with manufacturing, not exactly a new problem for Immunomedics, derail the company’s bid for glory.
Macrogenics’ safety scare could be contagious
It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.
Ash 2018 – Targeted AML trial expands its Beat
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.
Mid-cap investors see Eastern promise in the third quarter
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Civica Rx goes where generics companies fear to tread
A non-profit partnership of 500 hospitals wants to deliver its first generic drugs in 2019, lowering prices and stabilising supplies.
Mid and small caps provide another rocky ride in the second quarter
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.